Physician profile
Anna Yatskar
NPI 1750328688
$5,002.66
in general payments reported to CMS, 2019-2025
24 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,373 · 2020: $1,139 · 2021: $737 · 2022: $624 · 2023: $371 · 2024: $358 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,128.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,237.89 | 2019-2023 | |
| Lilly USA, LLC | $791.37 | 2019-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $658.45 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $359.00 | 2019-2025 | Evenity, Prolia, Prolia |
| Sanofi-Aventis U.S. LLC | $304.22 | 2020-2022 | |
| Horizon Therapeutics Plc | $283.59 | 2020-2022 | |
| Abbvie INC. | $247.38 | 2019-2023 | Vraylar |
| Indivior INC. | $162.73 | 2019-2021 | |
| Braeburn INC. | $114.79 | 2024-2025 | Brixadi |
| Currax Pharmaceuticals LLC | $109.16 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.54 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $93.30 | 2021 | |
| Allergan, INC. | $88.62 | 2019-2020 | |
| Amarin Pharma, INC. | $73.69 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.64 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $69.50 | 2021-2022 | |
| Intra-Sana Laboratories | $60.95 | 2023-2024 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Orexo US, INC. | $48.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $38.59 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.05 | 2025 | Trintellix |
| Metacel Pharmaceuticals LLC | $21.20 | 2023 | Ozobax |
| Genentech USA, INC. | $19.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $17.64 | 2019 | |
| Pfizer INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Yatskar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.